NCT03703427View on ClinicalTrials.gov

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2025

Conditions
Pathologic Residual Cancer Cells
Interventions
DRUG

Capecitabine, Oral, 500 Mg

1250mg/m2，d1-d14，q3w

DRUG

Vinorelbine Tartrate Oral

60mg/m2，d1；d8；q3w

Trial Locations (1)

Unknown

Zhiyong Yu, Jinan

All Listed Sponsors
lead

Zhiyong Yu

OTHER